Immix Biopharma (IMMX) Accumulated Expenses (2020 - 2026)
Immix Biopharma (IMMX) reported Accumulated Expenses of $880671.0 for Q1 2026, up 20.34% on a YoY basis from $731794.0 in Q1 2025, and down 6.53% sequentially from $942163.0 in Q4 2025.
Immix Biopharma (IMMX) Accumulated Expenses (2020 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 7 years of Accumulated Expenses data on file, last reported at $880671.0 in Q1 2026.
- For the quarter ending Q1 2026, Accumulated Expenses rose 20.34% year-over-year to $880671.0; the trailing twelve-month figure through Mar 2026 stood at $880671.0 (up 20.34% YoY), and the FY2025 full-year result was $942163.0, up 627.16% from the prior year.
- Accumulated Expenses declined to $880671.0 in Q1 2026, from $942163.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $942163.0 in Q4 2025 to a low of $9407.0 in Q1 2022.
- A 5-year average of $311351.2 and a median of $170632.0 in 2024 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses surged 4715.87% in 2022 and slumped 76.95% in 2023, its largest moves.
- Tracing IMMX's Accumulated Expenses over 5 years: stood at $438196.0 in 2022, then tumbled by 76.95% to $101007.0 in 2023, then increased by 28.28% to $129567.0 in 2024, then jumped by 627.16% to $942163.0 in 2025, then dropped by 6.53% to $880671.0 in 2026.
- Business Quant data shows IMMX's Accumulated Expenses at $880671.0 in Q1 2026, $942163.0 in Q4 2025, and $170896.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immix Biopharma | 487.25 Mn | 487.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 880,671.00 |
| Dec 31, 2025 | 942,163.00 |
| Sep 30, 2025 | 170,896.00 |
| Jun 30, 2025 | 52,940.00 |
| Mar 31, 2025 | 731,794.00 |
| Dec 31, 2024 | 129,567.00 |
| Sep 30, 2024 | 198,095.00 |
| Jun 30, 2024 | 170,632.00 |
| Mar 31, 2024 | 122,594.00 |
| Dec 31, 2023 | 101,007.00 |
| Sep 30, 2023 | 99,603.00 |
| Dec 31, 2022 | 438,196.00 |
| Mar 31, 2022 | 9,407.00 |
| Dec 31, 2021 | 9,099.00 |
| Dec 31, 2020 | 342,837.00 |